NasdaqCM:DARE

Stock Analysis Report

Executive Summary

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.

Share Price & News

How has Daré Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.8%

NasdaqCM:DARE

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-13.0%

NasdaqCM:DARE

9.6%

US Medical Equipment

2.1%

US Market

DARE underperformed the Medical Equipment industry which returned 9.1% over the past year.

DARE underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

DAREIndustryMarket
7 Day8.8%0.8%1.1%
30 Day13.7%0.2%3.7%
90 Day4.8%2.7%2.3%
1 Year-13.0%-13.0%10.5%9.6%4.4%2.1%
3 Yearn/a69.5%64.3%47.0%37.4%
5 Yearn/a132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Daré Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Daré Bioscience undervalued based on future cash flows and its price relative to the stock market?

2.86x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Daré Bioscience to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Daré Bioscience to establish if it is available at substantial discount.


Price Based on Earnings

Daré Bioscience is loss making, we can't compare its value to the US Medical Equipment industry average.

Daré Bioscience is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Daré Bioscience, we can't assess if its growth is good value.


Price Based on Value of Assets

Daré Bioscience is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Daré Bioscience expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

64.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Daré Bioscience is high growth as no revenue estimate data is available.

Daré Bioscience's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Daré Bioscience's revenue growth to the United States of America market average as no estimate data is available.

Daré Bioscience's earnings growth is expected to exceed the United States of America market average.

Daré Bioscience's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Daré Bioscience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Daré Bioscience performed over the past 5 years?

-63.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Daré Bioscience does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Daré Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Daré Bioscience's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Daré Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Daré Bioscience has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Daré Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Daré Bioscience's financial position?


Financial Position Analysis

Daré Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Daré Bioscience's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Daré Bioscience has no debt.

Daré Bioscience currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Daré Bioscience has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Daré Bioscience has less than a year of cash runway based on current free cash flow.

Daré Bioscience has less than a year of cash runway if free cash flow continues to grow at historical rates of 102.5% each year.


Next Steps

Dividend

What is Daré Bioscience's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Daré Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Daré Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Daré Bioscience has not reported any payouts.

Unable to verify if Daré Bioscience's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Daré Bioscience has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Daré Bioscience's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Sabrina Johnson (52yo)

4.3yrs

Tenure

0

Ms. Sabrina Martucci Johnson is the Founder and Chief Executive Officer of DARÉ Bioscience. Ms. Johnson serves as Secretary and Treasurer at Kyalin Biosciences, Inc. Ms. Johnson served as the Chief Operati ...


Management Age and Tenure

1.9yrs

Average Tenure

56yo

Average Age

The average tenure for the Daré Bioscience management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.2yrs

Average Tenure

63.5yo

Average Age

The average tenure for the Daré Bioscience board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$500,00015 Apr 19
Roger Hawley
EntityIndividual
Shares454,545
Max PriceUS$1.10

Ownership Breakdown


Management Team

  • Lisa Walters-Hoffert (60yo)

    Chief Financial Officer

    • Tenure: 2.5yrs
  • Sabrina Johnson (52yo)

    President

    • Tenure: 4.3yrs
  • Mark Walters (64yo)

    Vice President of Operations

    • Tenure: 4.7yrs
  • David Friend

    Chief Scientific Officer

    • Tenure: 1.3yrs
  • MarDee Haring-Layton (43yo)

    Vice President of Accounting & Finance

    • Tenure: 0yrs
  • John Fair

    Chief Business Officer

    • Tenure: 1.3yrs
  • Mary Jarosz

    Global Head of Regulatory Affairs

    • Tenure: 1.3yrs
  • John Katsilometes

    Controller

    • Tenure: 0yrs

Board Members

  • Bill Rastetter (71yo)

    Chairman of the Board

    • Tenure: 0.2yrs
  • Bob Langer (70yo)

    Member of Scientific Advisory Board

    • Tenure: 0.5yrs
  • Sabrina Johnson (52yo)

    President

    • Tenure: 4.3yrs
  • Susan Kelley (64yo)

    Director

    • Tenure: 2.2yrs
  • Robin Steele (63yo)

    Director

    • Tenure: 0yrs
  • Jessica Grossman

    Director

    • Tenure: 1.4yrs
  • Greg Matz (59yo)

    Director

    • Tenure: 1yrs

Company Information

Daré Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Daré Bioscience, Inc.
  • Ticker: DARE
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$14.515m
  • Shares outstanding: 16.68m
  • Website: https://www.darebioscience.com

Number of Employees


Location

  • Daré Bioscience, Inc.
  • 3655 Nobel Drive
  • Suite 260
  • San Diego
  • California
  • 92122
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DARENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2017
1221DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017

Biography

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The company intends to develop therapies in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 00:45
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.